Japanese

News Release

Entering into Collaboration Agreement with Immutep Ltd. for the supply of Eftilagimod Alpha

Eftilagimod Alpha (LAG-3Ig, efti or IMP321), developed by Immutep Ltd., is a soluble recombinant protein consisting of LAG-3 (Lymphocyte Activation Gene 3) and the Fc tail of a human IgG, and activates APCs (Antigen Presenting Cells) such as DCs (Dendritic Cells) through binding to HLA (Human Leucocyte Antigen) Class II molecule.
Under the supply and collaboration agreement, efti will be supplied as a component of Cytlimic’s proprietary combination adjuvant (with Poly-ICLC (Hiltonol®)) used in its peptide vaccines including CYT001 (antigen protein: HSP70 and GPC3).
Pre-clinical and clinical studies have shown that the combination of efti and Poly-ICLC (Hiltonol®) synergistically activates antigen-specific CTL (Cytotoxic T Lymphocyte) reactions, and furthermore the combination synergistically suppresses the expressions of major exhaustion markers of these cells (the combination is Cytlimic’s intellectual property).
“We are very excited to be working alongside Cytlimic to help evaluate efti as part of an innovative cancer vaccine that has potential as a new therapy. Efti is generating interest from around the world and following the agreements with Cytlimic, it is now being evaluated as part of three different combination therapy types: as a cancer vaccine-immunotherapy, as a chemo-immunotherapy and as an immuno-immunotherapy, showing its broad therapeutic potential,”, said Marc Voigt, CEO of Immutep.
Dr. Shun Doi, Cytlimic’s President and CEO said, “We are delighted with the engagement with Immutep, which will strongly help realize an innovative cancer vaccine-immunotherapy. Our own studies have shown that the combination of LAG-3Ig and Poly IC synergistically boost the efficacy of peptide vaccine, and thus I believe the combination of efti in our vaccine CYT001, which is also unique as an application of artificial intelligence, is an important step to add a new solution in cancer immunotherapy world.”
About Immutep:
Immutep is a globally active biotechnology company that is a leader in the development of immunotherapeutic products for the treatment of cancer and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximise value to shareholders. Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States. Immutep’s current lead product candidate is eftilagimod alpha (“efti” or “IMP321”), a soluble LAG-3Ig fusion protein based on the LAG-3 immune control mechanism. This mechanism plays a vital role in the regulation of the T cell immune response.
About Oncovir:
Oncovir, Inc. is a globally active biotechnology company dedicated to the development of nucleic-acid-based clinical therapies for cancer, infectious, immune, and degenerative disorders. Oncovir promotes Hiltonol (poly-ICLC) as an experimental viral mimic and broad activator of innate immunity. While initially developed as an interferon inducer, Hiltonol has much broader biological effects in humans, including specific antiviral, immune activating, vaccine adjuvant, and antitumor actions.

PAGETOP